Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.67 USD | -0.65% | -0.78% | +17.10% |
Apr. 18 | Maravai LifeSciences Unit Opens New Manufacturing Facility in San Diego | MT |
Apr. 10 | Craig-Hallum Initiates Coverage on Maravai LifeSciences With Buy Rating, $15 Price Target | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- Low profitability weakens the company.
- The company's enterprise value to sales, at 3.68 times its current sales, is high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.10% | 1.01B | B- | ||
-14.52% | 11.48B | A- | ||
+44.03% | 3.27B | D+ | ||
-33.09% | 2.2B | C | ||
-18.60% | 2.05B | - | B- | |
-27.59% | 1.49B | C+ | ||
-3.06% | 743M | C+ | ||
-33.50% | 413M | C- | ||
-46.94% | 377M | C- | ||
+27.44% | 374M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MRVI Stock
- Ratings Maravai LifeSciences Holdings, Inc.